Bayer's Sandra Peterson jumps to J&J, takes on consumer

Share this article:
Johnson & Johnson's latest shakeup is coming from the outside – the company is bringing on Sandra Peterson, chair and CEO of Bayer's CropScience division, to take hold of the US company's consumer units. Peterson's title will be group worldwide chairman and she will oversee the consumer unit, IT and global supply chain. She will join the New Jersey company December 1 and will also be part of J&J's executive committee. Peterson won't have much time to get over the jet lag – her last day at Bayer is officially November 30.

The move means Peterson will be put in charge of one of the J&J units that has become notable for its list of recalls, including OTC children's products and adult formulations of Tylenol, Benadryl, Sudafed and Sinutab. The division jump puts Peterson in familiar territory – she has also served as president and CEO of Bayer's medical care division and president of its diabetes business. This is in addition to her work at Medco, Nabisco and Whirlpool. It also moves her from overseeing a business that pulled in $9.4 billion last year to one that tallied $14.9 billion. For a one-to-one comparison, Bayer's healthcare unit, which includes animal, consumer and pharmaceutical businesses, had $22.2 billion in sales last year, compared to Johnson & Johnson's $14.9 billion.

It also puts Peterson in a parallel corporate situation, in that Bayer's consumer profile took a bit of a hit, with settlements over its Yaz birth control reaching around $400 million.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...